Kerry Holford - Credit Suisse Lars Hevreng - SEB Seamus Fernandez - Leerink Swann & Company Mark Clark - Deutsche Bank Damien Conover - Morningstar Naresh Chouhan - Liberum Capital Limited Presentation Pascal Soriot Hello everybody. It's Pascal
Schott - JPMorgan Vamil Divan - Credit Suisse Tony Butler - Barclays Gregg Gilbert - Bank of America Marc Goodman - UBS Damien Conover - Morningstar Alex Arfaei - BMO Capital Markets John Boris - SunTrust Presentation Operator Ladies and gentlemen
the line that they'll be able to replace those sales and bring the firm back to growth? [Morningstar analyst] Damien Conover , who covers Pfizer, thinks that the answer to that question is yes. He sees a lot of candidates that are either
Damien Conover : I am Damien Conover , director of pharmaceutical research at Morningstar. I'm ..... Thanks, Dave, and thanks everyone for joining me. I'm Damien Conover , director of pharmaceutical research at Morningstar. Thank
at is the pharmaceutical industry. I am here with Damien Conover , our director of pharmaceutical research, to take a closer look. Damien, thanks for joining me today. Damien Conover : Thanks for having me, Jeremy. Glaser: So, let
market over the last year. I'm here today with Damien Conover , director of pharmaceutical research, to see if ..... so where it is. Damien, thanks for joining me. Damien Conover : Thanks for having me, Jeremy. Glaser: As a sector
Amylin ranked Number 18 in Morningstar's annual biotechnology takeout list as our view of the company's strong need for a partner was tempered by fairly disappointing pipeline prospects. Damien Conover , CFA contributed to this note.
rating. Given how close AA firms trade to AA- rated firms, though, we wouldn't anticipate significant changes to the trading levels of Sanofi's debt based on this transaction. Damien Conover , CFA, also contributed to this note.
the long run, we expect the acquisition will give Novartis increased exposure to the quickly growing eye-care business (second only to oncology drug growth over the past five years). Damien Conover , CFA, contributed to this note.
candidate that posted blockbuster-worthy data this summer. As Bristol approaches its patent cliff, its use of capital with these bolt-on acquisitions becomes increasingly important. Damien Conover , CFA, also contributed to this note.